Treatment of Bronchitis in COPD

First-Line Bronchodilator Therapy

The American Thoracic Society recommends ipratropium bromide as first-line therapy to improve cough in stable COPD patients with chronic bronchitis (Grade A recommendation) 1
Standard dosing is ipratropium bromide 36 μg (2 inhalations) four times daily 2, 3
Short-acting β-agonists should be used to control bronchospasm and relieve dyspnea; they may also reduce chronic cough in some patients (Grade A recommendation) 1, 4

For patients with low symptom burden and low exacerbation risk, the European Respiratory Society suggests starting with a bronchodilator to reduce breathlessness 2
For patients with severe airflow obstruction (FEV1 <50%) or frequent exacerbations, consider adding an inhaled corticosteroid with a long-acting β-agonist 5, 6

The American College of Chest Physicians recommends antibiotics for acute exacerbations of chronic bronchitis, particularly for patients with severe exacerbations and those with more severe airflow obstruction at baseline (Grade A recommendation) 1, 7
During acute exacerbations, both short-acting β-agonists and anticholinergic bronchodilators should be administered 4
A short course (10-15 days) of systemic corticosteroid therapy is recommended for acute exacerbations; IV therapy for hospitalized patients and oral therapy for ambulatory patients 5, 4

Theophylline may be considered to control chronic cough in stable patients with chronic bronchitis, but careful monitoring for complications is necessary (Grade A recommendation) 1, 4
Roflumilast may be considered for patients with severe COPD with characteristics of chronic bronchitis and a history of exacerbations 6

Long-term prophylactic therapy with antibiotics is not recommended for stable patients with chronic bronchitis (Grade I recommendation) 1, 7
Currently available expectorants have not been proven effective for cough in chronic bronchitis and should not be used 5, 4

Smoking cessation is the most effective means to improve or eliminate the cough of chronic bronchitis, with 90% of patients reporting resolution of cough after smoking cessation 7
For troublesome cough that requires temporary suppression, codeine and dextromethorphan can be effective, reducing cough counts by 40-60% 5, 8

For patients with mild disease, a short‑acting β‑agonist may be added as needed to relieve symptoms such as breathlessness. 9
Adding a LABA/ICS combination to anticholinergic therapy improves health‑related quality of life and lowers the risk of COPD exacerbations in individuals with severe airflow limitation or frequent exacerbations. 10

Inhaled corticosteroids should be combined with a LABA (never used as monotherapy) for patients with severe obstruction or recurrent exacerbations. 10
LABA/ICS therapy modestly slows lung‑function decline, achieving roughly half the benefit observed with smoking cessation. 10
Patients exhibiting the chronic bronchitis phenotype and a history of exacerbations respond preferentially to regimens that include an inhaled corticosteroid. 10
Individuals with two or more exacerbations in the prior year demonstrate greater benefit from preventive treatment that incorporates an inhaled corticosteroid. 10

For patients requiring long‑acting bronchodilation, LAMAs (e.g., tiotropium) are superior to LABAs in reducing COPD exacerbations and related hospitalizations. 10
Meta‑analyses show LAMAs reduce exacerbation frequency more than twice‑daily LABAs, with no difference in mortality or all‑cause hospital admissions. 10

Oral corticosteroids are recommended (Grade A evidence) for a short course during acute exacerbations, but should not be continued long‑term in stable chronic bronchitis. 9
Postural drainage and chest physiotherapy have not demonstrated benefit for chronic bronchitis cough and are not recommended. 9

Smoking cessation provides the greatest improvement in chronic bronchitis cough, with the majority of patients experiencing resolution, and yields twice the benefit on lung‑function decline compared with inhaled medications. 10